RxDoctor Payments Data

Satheesh Nair, MD

Gastroenterology · Memphis, TNNPI 1700822384

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $274,686 of the $349,281 with a category attached, or 78.6%. 19 manufacturers reported payments, led by Gilead at 28.6% of the total. Among gastroenterology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$349,281in general payments, 2019–2025

Across 347 payments — averaging $1006.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$100K
  • Intercept Pharmaceuticals, Inc.$97K
  • Mallinckrodt Hospital Products Inc.$49K
  • Madrigal Pharmaceuticals$32K
  • AbbVie$20K
  • Mirum Pharmaceuticals, Inc.$15K
  • plus $36K from 13 others

What the payments were for

  • Consulting fees$31,3199%
  • Speaking & faculty fees$274,68679%
  • Travel & lodging$31,3299%
  • Food & beverage$11,9103%
  • Education$370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$349,281 in reported general payments places this provider in the 95th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$56,184
Medicare patients
186
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin63$200,450
VemlidyTenofovir Alafenamide45$63,332
Envarsus XrTacrolimus33$19,290
Tacrolimus196$19,104
EliquisApixaban13$14,475
Sirolimus37$14,242
PrografTacrolimus16$11,419
Mycophenolate Mofetil83$7,261
Ursodiol71$5,938
XareltoRivaroxaban11$5,867
Entecavir74$5,496
Mycophenolic AcidMycophenolate Sodium19$4,409
Cyclosporine14$4,331
Lamivudine20$1,523
Lactulose26$1,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,208$200,45063 claims
GileadVemlidy$99,754$63,33245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →